Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverage M&A to offset the massive patent cliff approaching in 2028. Fair value range: low $94.9, high $147, with mid-point at $121.
Stock analysis
Merck & Co. Inc.MRK Merck & Co. Inc. fair value $121–$147
Heavy concentration risk in Keytruda, which faces loss of exclusivity in 2028.
Dependency on future M&A and ADC pipeline execution to replace lost revenue.
Primary valuation anchor focuses on near-term forward earnings over stale trailing cash flows.
Fair value
$121
Margin of safety
+6.9%
Confidence
84/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$112.30Price
FV $120.61
High $146.75
Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverage M&A to offset the massive patent cliff approaching in 2028.
Intangible Assets (Patents)
Intangible Assets (Patents)
Economies of Scale
Economies of Scale
Cycle upside
Accelerating M&A and robust pipeline readouts across the biopharma sector.
§2 กรณีลบ
A severe stress test assumes structural earnings decline post-2028 as Keytruda revenues drop, combined with a failure to realize ADC revenue and M&A integration issues, compressing gross margins.
วิธีที่ธีสิสนี้อาจล้มเหลว
Severe Keytruda Cliff
· High
Failure to offset Keytruda LOE through M&A or internal ADC pipeline leaves a massive revenue gap, severely compressing structural margins.
FV impact
Down to $94.87
Trigger
2028-2030
ADC Pipeline Failure
· Medium
Late-stage clinical failures in the Antibody-Drug Conjugate pipeline erode future growth vectors, stalling the dividend trajectory.
FV impact
Loss of terminal growth and multiple derating
Trigger
2026-2028
Draconian IRA Pricing
· Medium
Aggressive regulatory pricing pressures from the IRA compress margins more sharply than modeled, stunting near-term operating cash flows.
FV impact
Terminal margin deterioration
Trigger
2026-2029
สัญญาณเตือนล่วงหน้าที่ต้องเฝ้าระวัง
ตัวชี้วัด
ปัจจุบัน
เกณฑ์ทริกเกอร์
Slowdown in Keytruda quarterly sales growth pre-2028
Monitor
Deterioration versus the report thesis
Negative FDA decisions on late-stage ADC candidates
Monitor
Deterioration versus the report thesis
Escalating R&D costs without proportional revenue gains
Monitor
Deterioration versus the report thesis
Unfavorable shifts in gross margin trajectories
Monitor
Deterioration versus the report thesis
Management signaling a pause or slowing of dividend growth
Monitor
Deterioration versus the report thesis
§3 ประวัติการเงิน
งบกำไรขาดทุน — หกงวดล่าสุด
รายการ
T−0
T−1
T−2
T−3
CAGR
ช่วงเวลา
2022-12-31
2023-12-31
2024-12-31
2025-12-31
Trend
รายได้
$59.28B
$60.12B
$64.17B
$65.01B
+3.1%
กำไรขั้นต้น
$41.87B
$43.99B
$48.98B
$48.63B
+5.1%
กำไรจากการดำเนินงาน
$18.28B
$2.95B
$20.22B
$22.11B
+6.5%
กำไรสุทธิ
$14.52B
$365.0M
$17.12B
$18.25B
+7.9%
EPS (เจือจาง)
$5.71
$0.14
$6.74
$7.28
+8.4%
EBITDA
$21.32B
$6.91B
$25.71B
$28.26B
+9.9%
R&D
$13.55B
$30.53B
$17.94B
$15.79B
+5.2%
SG&A
$10.04B
$10.50B
$10.82B
$10.73B
+2.2%
คะแนนคุณภาพ
Piotroski F-score
4 / 9
คะแนนคุณภาพรวม 0–9
Altman Z-score
3.87
ความเสี่ยงล้มละลาย (>3 ปลอดภัย)
Beneish M-score
-2.27
ความเสี่ยงการบิดเบือนกำไร
OCF / กำไรสุทธิ
0.9×
>1 บ่งบอกคุณภาพกำไรสูง
เกณฑ์คุณภาพบัญชี
Pass
เกณฑ์ปรับตามภาคอุตสาหกรรม
ROIC
17.4%
ผลตอบแทนต่อทุนที่ลงทุน
ส่วนที่ 3
Numbers analysis
กระแสเงินสด
Cash-flow quality is reflected in the OCF / net income, accounting-quality, and ROIC rows above.
การจัดสรรทุน
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
สมาชิกรายบุคคล — §4 เป็นต้นไปอีก 11 ส่วน
อ่านวิเคราะห์เต็มฉบับ — อีก 11 ส่วน
Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.
Based on our latest independent analysis, MRK looks modestly undervalued. The current price is $112 versus a composite fair-value midpoint of $121 (range $94.9–$147), which implies roughly 7.4% upside to the midpoint.
Our composite fair-value range for MRK is $94.9–$147, with a midpoint of $121. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for Merck & Co. Inc.'s archetype.
Our current rating for MRK is Hold with a confidence score of 84/100. Hold. Current price of $112.30 represents limited upside of 7.4% to our $120.61 fair value mid-point, appropriately pricing in the pipeline transition risks. This is independent research for educational purposes, not personalized investment advice.
The top risks our latest report flags for Merck & Co. Inc. are: Severe Keytruda Cliff; ADC Pipeline Failure; Draconian IRA Pricing. The single biggest risk is Severe Keytruda Cliff: Failure to offset Keytruda LOE through M&A or internal ADC pipeline leaves a massive revenue gap, severely compressing structural margins.
Our current rating for MRK is Hold, issued with a confidence score of 84/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($94.9–$147) versus the current price of $112.
Merck & Co. Inc. is classified as a mature-dividend stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for MRK.
